A Phase 4 interventional study of Celecoxib and Naproxen in Arthritis, Juvenile Rheumatoid, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 39 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.
Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 12th largest by enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2009, is one of 7 in phase 4, and was the 28th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 35
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, France and 5 more countries
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 18 · Phase 3 32 · Phase 4 7
First in 1994; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 55 across the 83 interventional studies, 288 across the 24 observational. Of the 75 that completed or were terminated, 46 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 109 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 2 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Juvenile with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 109 studies in Arthritis, Juvenile with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Celecoxib
Drug: Naproxen
Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit
Value at 6 weeks minus value at baseline.
Time frame: 6 Weeks/Final Visit
Change From Baseline to Week 2 in SBP.
Value at 2 weeks minus value at baseline.
Time frame: 2 weeks
Change From Baseline in SBP at Week 4.
Value at 4 weeks minus value at baseline.
Time frame: 4 weeks
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 2.
Value at 2 weeks minus value at baseline.
Time frame: 2 weeks
Change From Baseline in DBP at Week 4.
Value at 4 weeks minus value at baseline.
Time frame: 4 weeks
Change From Baseline in DBP at Week 6/Final Visit
Value at 6 weeks/Final Visit minus value at baseline.
Time frame: 6 weeks
Change From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit.
The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.
Time frame: 6 weeks
Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit.
The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.
Time frame: Week 6/Final Visit
Change From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit.
Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.
Time frame: 6 weeks
Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit.
Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.
Time frame: Week 6/Final Visit
Change From Baseline in Assessment of Ambulatory Blood Pressure Monitoring (ABPM) for SBP and DBP at Week 6/Final Visit
Ambulatory BP measurements were obtained from 24 participants(in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. BP was monitored by a 24 hour Ambulatory BP device provided by a central vendor.
Time frame: 6 weeks/Final Visit
Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit
Ambulatory BP measurements were obtained from 24 participants (in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure.
Time frame: 6 weeks/Final Visit
Change From Baseline in Assessment of ABPM for SBP and DBP Pressure at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)
A summary of ABPM 24-hour averages for SBP and DBP are presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).
Time frame: 6 weeks/Final Visit
Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant)
A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).
Time frame: 6 weeks/Final Visit
This was a phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial in participants with juvenile idiopathic arthritis (JIA). A total of 221 participants were screened into the study in 32 investigator sites.
| Milestone | Celecoxib | Naproxen |
|---|---|---|
| Started | 100 | 98 |
| Completed | 88 | 94 |
| Not completed | 12 | 4 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Other | 1 | 2 |
Value at 6 weeks minus value at baseline.
| mmHg (millimeter of mercury) | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit | 0.366 ± 0.70 | -0.734 ± 0.70 |
Value at 2 weeks minus value at baseline.
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline to Week 2 in SBP. | -0.202 ± 0.53 | -1.290 ± 0.53 |
Value at 4 weeks minus value at baseline.
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in SBP at Week 4. | -0.170 ± 0.58 | -2.007 ± 0.58 |
Value at 2 weeks minus value at baseline.
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) at Week 2. | -1.346 ± 0.52 | -0.139 ± 0.52 |
Value at 4 weeks minus value at baseline.
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in DBP at Week 4. | -0.628 ± 0.54 | -0.848 ± 0.54 |
Value at 6 weeks/Final Visit minus value at baseline.
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in DBP at Week 6/Final Visit | -0.535 ± 0.54 | -0.356 ± 0.54 |
The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.
| mm (millimeter) | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in Parent's Assessment of Overall Well-being at Week 6/Final Visit. | -10.581 ± 2.081 | -13.614 ± 2.060 |
The parent/legal guardian evaluated the participant's overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the visual analog scale (VAS). The VAS ranged from 0 to 100, with 0 being 'very well' and 100 being 'very poor.
| Participants | Celecoxib | Naproxen |
|---|---|---|
| Number of Participants With >= 30% Improvement in the Parent's Global Assessment of Overall Well-being at Week 6/Final Visit. | 47 | 54 |
Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.
| mm | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in Participant's Assessment of Overall Well-being at Week 6/Final Visit. | -12.990 ± 2.226 | -12.588 ± 2.115 |
Participants, ≥8 years of age at the baseline, evaluated their own overall well-being at Baseline and at Week 6 (or Final Visit) by placing one vertical line on the VAS. The VAS ranges from 0 to 100, with 0 being 'very well' and 100 being 'very poor'.
| Participants | Celecoxib | Naproxen |
|---|---|---|
| Number of Participants With >= 30% Improvement in the Participant's Global Assessment of Overall Well-being at Week 6/Final Visit. | 33 | 45 |
Ambulatory BP measurements were obtained from 24 participants(in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. BP was monitored by a 24 hour Ambulatory BP device provided by a central vendor.
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| SBP | 2.4 ± 7.02 | -1.7 ± 12.40 |
| DBP | 0.9 ± 4.23 | -1.1 ± 5.36 |
Ambulatory BP measurements were obtained from 24 participants (in addition to the BP measurements obtained by the cuff technique) participating in the exploratory 24-hour ABPM sub-study. A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure.
| bpm (beats per minute) | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit | 2.5 ± 6.34 | 3.7 ± 8.50 |
A summary of ABPM 24-hour averages for SBP and DBP are presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).
| mmHg | Celecoxib | Naproxen |
|---|---|---|
| SBP | 2.4 ± 7.02 | 1.9 ± 4.13 |
| DBP | 0.9 ± 4.23 | 0.3 ± 2.86 |
A summary of ABPM 24-hour averages for heart rate is presented in this Outcome Measure. One of the participant in the Naproxen ABPM Arm had clinically implausible high BP values at Baseline. Due to the low number of participants in each Arm (12 and 11) these values had a significant impact on the mean baseline values for the Naproxen Arm. As a result, an additional sensitivity analysis was conducted, excluding this participant (Participant ID 10031002).
| bpm | Celecoxib | Naproxen |
|---|---|---|
| Change From Baseline in Assessment of ABPM for Heart Rate at Week 6/Final Visit (Sensitivity Analysis Excluding One Participant) | 2.5 ± 6.34 | 3.3 ± 8.82 |
Collected over Up to Week 6/Final Visit. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 0/100 (0%) | 10/100 (10%) |
| Naproxen | — | 1/98 (1%) | 18/98 (18.4%) |
| Event | Celecoxib | Naproxen |
|---|---|---|
| Hand fractureInjury, poisoning and procedural complications | 0/100 | 1/98 |
| Event | Celecoxib | Naproxen |
|---|---|---|
| NauseaGastrointestinal disorders | 4/100 | 9/98 |
| HeadacheNervous system disorders | 7/100 | 4/98 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/100 | 5/98 |
| Age, Customized(Participants) | Celecoxib | Naproxen | Total |
|---|---|---|---|
| >=2 - <8 Years | 22 | 18 | 40 |
| >=8 - <13 Years | 34 | 47 | 81 |
| >=13 - <18 Years | 44 | 33 | 77 |
| Sex: Female, Male(Participants) | Celecoxib | Naproxen | Total |
|---|---|---|---|
| Female | 76 | 64 | 140 |
| Male | 24 | 34 | 58 |
The record gives a start of Sep 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Celecoxib · Naproxen
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →